Long-Term Complete Response in Metastatic Poorly-Differentiated Neuroendocrine Rectal Carcinoma with Multimodal Approach. A Case Report Abstract #2740

Introduction: Rectal neuroendocrine carcinomas (NEC) are extremely rare and account for less than 1% of colorectal malignancies.
Aim(s): Due to aggressive growth and rapid metastatic diffusion, early diagnosis and multidisciplinary approach are mandatory.
Materials and methods: On July 2015 a 42 year-old patient arrived to our Emergency Department for rectal bleeding. Colonoscopy showed an ulcerated lesion at 12 cm from the anal verge; biopsies revealed a NEC G3 ki67 90%. MRI, CT and PET scan showed rectal localization and regional nodal involvement, without metastatic disease. He started first-line chemotherapy with Cisplatinum and Etoposide with Progression Disease and worsening of local symptoms after three cycles. Surgery was recommended and the patient underwent an open anterior low rectal resection with terminal colostomy. Histological report confirmed a small-cells NEC pT3N2b, G3, ki67 98%, with negative surgical margins. The first post-operative total-body CT scan showed an early relapse of disease with an 85 mm pelvic lesion. The patient underwent second line chemotherapy with FOLFIRI and 50Gy radiotherapy (RT). On March 2016 CT-PET imaging showed pelvic Complete Response (CR), although pathological interaortocaval lymph-nodes appeared. Because of low sensibility to systemic treatment we proposed a 45Gy radiotherapy on metastatic sites with Progressive Response.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Case reports
Presenting Author: Medical Doctor Pietro Maria Lombardi

To read results and conclusion, please login ...

Further abstracts you may be interested in

#2699 Dacarbazine- or Temozolomide-Based Chemotherapy in Metastatic Digestive Neuroendocrine Carcinomas in Post First-line Chemotherapy: A Retrospective Multicentric Study of the French Group of Endocrine Tumours (GTE)
Introduction: First-line chemotherapy in metastatic neuroendocrine carcinomas (NEC) is based on etoposide and platinum. However, there is no standard for second line treatment.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Thomas Couronne
Authors: Couronne T, Fine C, Hadoux J, Lecomte T, ...
#2701 Assessing the Gaps in Experience and Knowledge of Australian Primary Health Care Professionals (GPs), in Treating and Caring for the Increasing Number of Australian Neuroendocrine Tumour (NET) Patients
Introduction: Conservatively,the incidence of NETs is 7 / 000' p.a, however,the prevalence of patients living with NETs is higher,40/000',making it the 2nd most common GI malignancy after colorectal cancer.Patients are living longer,however,with impaired quality of life.Management of debilitating symptoms such as diarrhoea,fatigue,anxiety,and flushing are complex and heterogenous.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Trials in Progress/Trials in Concept
Presenting Author: Simone Leyden
Authors: Leyden S, Cummins M, Wakelin K, ...
#2716 Neuroendocrine Carcinoma of the Upper Urinary Tract: A Case Report
Introduction: There are no dedicated guidelines for treatment of urothelial NEC given disease rarity. An aggressive approach, including neoadjuvant cisplatin-based chemotherapy + nephroureterectomy and adjuvant platinum-based chemotherapy, is recommended.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Case reports
Presenting Author: Dr Roberta Elisa Rossi
#2730 FOLFIRINEC, A Multi-Center, Randomized, Comparative Phase II Study of FOLFIRINOX vs Platinum-Etoposide as First Line Treatment for Metastatic Neuroendocrine Carcinoma of Gastroenteropancreatic or Unknown Origin, Associated with Molecular Profiling
Introduction: Grade 3 (G3) gastroenteropancreatic (GEP) neuroendocrine carcinoma (NEC) are rare diseases with a poor prognosis. FOLFIRINEC is a multicenter comparative phase II study of mFOLFIRINOX vs platinum-etoposide (PE) as first line treatment for metastatic G3 NEC of GEP or unknown origin.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Trials in Progress/Trials in Concept
Presenting Author: Dr Julien Hadoux
#2769 Treatment Outcomes of Patients with G3 Neuroendocrine Neoplasms
Introduction: Extra-pulmonary neuroendocrine carcinomas (NEC) and neuroendocrine tumors (NET) G3 are aggressive neoplasia associated with a limited prognosis.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Medical treatment - Chemotherapy Somatostatin analogues, Interferon
Presenting Author: Josephine Schenk